⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6231639 | 0.83 | PKM (0.41) | — | |
| SCHEMBL6227662 | 0.83 | PKM (0.46) | — | |
| SCHEMBL20294175 | 0.82 | GRM1 (0.34) | — | |
| SCHEMBL9142496 | 0.79 | GRM1 (0.50) | — | |
| SCHEMBL1648486 | 0.79 | GRM1 (0.50) | — | |
| Hydrochloric Acid SCHEMBL5480359 | 0.76 | GRM1 (0.48) | — | |
| Hydrochloric Acid SCHEMBL8368069 | 0.76 | GRM1 (0.48) | — | |
| SCHEMBL6226927 | 0.76 | PKM (0.35) | — | |
| SCHEMBL20294165 | 0.75 | FFAR3 (0.36) | — | |
| SCHEMBL6228367 | 0.73 | PKM (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219492-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-08-02 | — | — | EP | claimed |
| EP-3790877-B1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | INCYTE CORP (US) | 2023-03-01 | — | — | EP | claimed |
| US-20220348594-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-11-03 | — | — | US | claimed |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-06-23 | — | — | US | claimed |
| CN-112752756-A | Tetrahydro-imidazo [4,5-c ] pyridine derivatives as PD-L1 immunomodulators | 因赛特公司 | 2021-05-04 | — | — | CN | claimed |
| US-20210115068-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-04-22 | — | — | US | claimed |
| EP-3790877-A1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | Incyte Corporation (US) | 2021-03-17 | — | — | EP | claimed |
| US-10906920-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2021-02-02 | — | — | US | claimed |
| US-20200277309-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-09-03 | — | — | US | claimed |
| CN-110582493-A | Benzoxazole derivatives as immunomodulators | 因赛特公司 | 2019-12-17 | — | — | CN | claimed |
| US-20190345170-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-11-14 | — | — | US | claimed |
| WO-2019217821-A1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2019-11-14 | — | — | WO | claimed |
| EP-3558985-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | claimed |
| WO-2018119266-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | claimed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | claimed |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| EP-4219492-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-08-02 | — | — | EP | disclosed |
| US-10308644-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2018119266-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |